LXS196
10mM in DMSO
- Product Code: 201760
CAS:
1874276-76-2
| Molecular Weight: | 472.47 g./mol | Molecular Formula: | C₂₂H₂₃F₃N₈O |
|---|---|---|---|
| EC Number: | MDL Number: | ||
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | -20°C |
Product Description:
LXS196 is a selective inhibitor of the mitogen-activated protein kinase (MEK) pathway, specifically targeting MEK1 and MEK2 enzymes. It is primarily investigated for its potential in treating cancers driven by mutations in the RAS/RAF/MEK/ERK signaling cascade. Notably, LXS196 has shown promise in preclinical and clinical studies for the treatment of advanced or metastatic uveal melanoma, a rare form of melanoma that often harbors GNAQ or GNA11 mutations leading to MEK pathway activation.
The compound is being evaluated in clinical trials, either as a monotherapy or in combination with other agents such as PKC inhibitors or immune checkpoint inhibitors, to enhance antitumor efficacy. Its ability to penetrate the blood-brain barrier also makes it a candidate for treating melanoma with central nervous system involvement. Due to its targeted mechanism, LXS196 offers a therapeutic strategy for patients with limited treatment options, particularly those with tumors resistant to conventional therapies.
Sizes / Availability / Pricing:
| Size | Availability | Price | Quantity |
|---|---|---|---|
| 1ml | 10-20 days | ฿11,800.00 |
+
-
|
LXS196
LXS196 is a selective inhibitor of the mitogen-activated protein kinase (MEK) pathway, specifically targeting MEK1 and MEK2 enzymes. It is primarily investigated for its potential in treating cancers driven by mutations in the RAS/RAF/MEK/ERK signaling cascade. Notably, LXS196 has shown promise in preclinical and clinical studies for the treatment of advanced or metastatic uveal melanoma, a rare form of melanoma that often harbors GNAQ or GNA11 mutations leading to MEK pathway activation.
The compound is being evaluated in clinical trials, either as a monotherapy or in combination with other agents such as PKC inhibitors or immune checkpoint inhibitors, to enhance antitumor efficacy. Its ability to penetrate the blood-brain barrier also makes it a candidate for treating melanoma with central nervous system involvement. Due to its targeted mechanism, LXS196 offers a therapeutic strategy for patients with limited treatment options, particularly those with tumors resistant to conventional therapies.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Purchase History for
Loading purchase history...
Cart
No products
Subtotal:
฿0.00
฿0.00
Total :